Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 14/20 | 0.70 |
| ▸ | PGR | P06401 | 7/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659894 | 0.93 | NR3C1 (0.70) | NR3C1NR3C2PGR | |
| SCHEMBL3745184 | 0.92 | NR3C1 (0.68) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL291671 | 0.92 | NR3C1 (0.86) | NR3C1NR3C2PGR | |
| SCHEMBL4447862 | 0.89 | NR3C1 (0.71) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL3799600 | 0.87 | NR3C1 (0.75) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL3814315 | 0.86 | NR3C1 (0.64) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL293433 | 0.85 | NR3C1 (0.83) | NR3C1NR3C2PGR | |
| SCHEMBL292874 | 0.84 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL292809 | 0.84 | NR3C1 (0.86) | NR3C1NR3C2PGR | |
| SCHEMBL292490 | 0.84 | NR3C1 (0.85) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| EP-2203160-A1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | Bausch & Lomb Incorporated (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2190431-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST FOR TREATING OR CONTROLLING ANTERIOR-SEGMENT INFLAMMATION | Bausch & Lomb Incorporated (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2051736-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009042377-A1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | BAUSCH & LOMB INCORPORATED (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009023471-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST FOR TREATING OR CONTROLLING ANTERIOR-SEGMENT INFLAMMATION | BAUSCH & LOMB INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | NR3C1 3/4885NR3C2 18/4885PGR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.